Imcivree received European Commission approval last year for treating obesity and control of hunger in adults and children six years and older with pro-opiomelanocortin or leptin receptor deficiency, the US commercial-stage biopharmaceutical company said.
Price: 4.14, Change: -0.06, Percent Change: -1.43